Translate Bio, Inc

(NASDAQ:TBIO)

Latest On Translate Bio, Inc (TBIO):

Date/Time Type Description Signal Details
2023-06-01 01:44 ESTNewsTelesis Bio gets $28 million in financing through preferred stock private placementN/A
2023-05-12 01:20 ESTNewsCodex DNA GAAP EPS of -$0.37 in-line, revenue of $6.31M misses by $1.09MN/A
2023-03-25 22:45 ESTNewsTelesis Bio, Inc. (TBIO) Q4 2022 Earnings Call TranscriptN/A
2023-03-22 02:04 ESTNewsCodex DNA GAAP EPS of -$0.28 beats by $0.13, revenue of $9.47M beats by $2.27MN/A
2023-01-05 00:42 ESTNewsTelesis Bio GAAP EPS of -$0.42 beats by $0.05, revenue of $6.68M beats by $1.38M; raises FY22 revenue outlookN/A
2023-01-04 10:54 ESTNewsTelesis Bio, Inc. (DNAY) Q3 2022 Earnings Call TranscriptN/A
2021-08-30 20:08 ESTNewsSanofi withdraws, refiles Translate Bio acquisition with U.S. antitrust regulatorsN/A
2021-08-26 01:29 ESTNewsSanofi - Translate Bio deal to come under increased FTC scrutiny - DealreporterN/A
2021-08-03 19:31 ESTNewsSanofi to acquire Translate Bio for $3.2B to boost mRNA technologyN/A
2021-08-03 00:30 ESTNewsTranslate Bio surges in after hours on report of Sanofi bid (update)N/A
2021-07-30 21:49 ESTNewsAfter hot streak, Translate Bio shares fall 16% in morning tradingN/A
2021-07-26 23:12 ESTNewsTranslate Bio climbs to a five-month high after Street-high target from RothN/A
2021-07-24 01:33 ESTNewsPfizer/BioNTech COVID-19 shot is 39% effective with prevalence of Delta variant, Israel saysN/A
2021-07-22 03:46 ESTNewsTranslate Bio gets $50M mRNA vaccine program milestone payment from Sanofi PasteurN/A
2021-07-22 03:36 ESTNewsSanofi, Translate Bio launch Phase 1 trial of mRNA influenza vaccineN/A
2021-07-22 03:36 ESTNewsCureVac’s setback in COVID-19 vaccine trial could foretell trouble for Arcturus and Translate Bio: analystsN/A
2021-07-22 03:30 ESTNewsCerevel Therapeutics, Avinger leads healthcare gainers; DiaMedica Therapeutics, MediWound among major losersN/A
2021-05-06 20:03 ESTNewsTranslate Bio misses on revenueN/A
2021-04-29 21:56 ESTNewsSanofi remains hopeful in ‘finding a place’ in COVID-19 vaccine raceN/A
2021-04-23 21:39 ESTNewsTranslate Bio: New Management, Aggressive mRNA Pipeline Development, And Substantial UpsideN/A
2021-04-19 18:00 ESTNewsTranslate Bio names Brendan Smith CFON/A
2021-04-19 18:00 ESTNewsTranslate Bio's MRT5500 shows favorable immune response & efficacy against SARS-CoV-2, shares rise 4%N/A
2021-03-23 11:00 ESTNewsIonis viewed favorably despite trial setback; BioLife Solutions upgraded at Benchmark in today’s analyst actionN/A
2021-03-22 15:25 ESTNewsTranslate Bio names Rand Sutherland presidentN/A
2021-03-19 03:19 ESTNewsTranslate Bio downgraded after Cystic Fibrosis data; Agilent upgrade and more in today’s analyst actionN/A
2021-03-19 03:18 ESTNewsTranslate Bio falls as Wall Street downgrades the stock after trial setbackN/A
2021-03-18 13:41 ESTAnalyst RatingThe Analyst Target Price has decreased from $32.38 to $32.Neutral
2021-03-18 06:22 ESTNewsTranslate Bio’s Cystic Fibrosis therapy fails to improve lung function in Phase 1/2 trialN/A
2021-03-12 12:24 ESTNewsSanofi, Translate Bio (TBIO) on go with study of mRNA COVID-19 vaccine candidateN/A
2021-03-11 12:31 ESTAnalyst RatingThe Analyst Target Price has decreased from $32.5 to $32.38.Neutral
2021-03-04 12:36 ESTEarnings EstimateAn EPS average of -$0.39 is estimated for the 2022 year.Sell
2021-03-04 12:36 ESTEarnings EstimateAn EPS average of -$0.27 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-02 12:35 ESTAnalyst RatingThe Analyst Target Price has increased from $32.25 to $32.5.Buy
2021-02-27 00:47 ESTFinancialsCompany financials have been released.Neutral
2021-01-18 08:35 ESTAnalyst RatingThe Analyst Target Price has increased from $31.88 to $32.25.Buy
2021-01-08 08:05 ESTNewsTranslate Bio completes enrolment in early-stage MRT5005 study, expects data in Q2 2021N/A
2021-01-04 15:31 ESTNewsTranslate Bio: Translating mRNA To Protein Expression Into TherapiesN/A
2020-12-23 17:08 ESTAnalyst RatingThe Analyst Target Price has increased from $31 to $31.88.Buy
2020-12-23 02:49 ESTNewsTranslate Bio finance chief departsN/A
2020-12-05 01:04 ESTAnalyst RatingThe Analyst Target Price has increased from $30.13 to $31.Buy
2020-11-26 21:43 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 09:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $30.75 to $30.13.Neutral
2020-11-23 09:07 ESTAnalyst RatingThe Analyst Target Price has increased from $30.38 to $30.75.Buy
2020-11-10 13:15 ESTAnalyst RatingThe Analyst Target Price has increased from $29.88 to $30.38.Buy
2020-11-09 21:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 13:35 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-09 13:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $30 to $29.88.Neutral
2020-11-08 01:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:17 ESTFinancialsCompany financials have been released.Neutral
2020-10-20 05:24 ESTNewsTranslate's Covid-Vaccine, And Other News: The Good, Bad And Ugly Of BiopharmaN/A

About Translate Bio, Inc (TBIO):

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.

TBIO Quotes by TradingView

See Advanced Chart

General

  • Name Translate Bio, Inc
  • Symbol TBIO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 122
  • Fiscal Year EndDecember
  • IPO Date2018-06-28
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.translate.bio
View More

Valuation

  • Forward PE 29.67
  • Price/Sales (Trailing 12 Mt.) 12.5
  • Price/Book (Most Recent Quarter) 5.42
  • Enterprise Value Revenue 9.67
  • Enterprise Value EBITDA 497.58
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.13
  • Next Year EPS Estimate -$0.35
  • Next Quarter EPS Estimate -$0.10
  • Profit Margin -39%
  • Operating Margin -5%
  • Return on Assets -1%
  • Return on Equity -21%
  • Revenue 138.81 million
  • Earnings Per Share -$2.40
  • Revenue Per Share $2.06
  • Gross Profit 79.28 million
  • Quarterly Earnings Growth 1221.1%
View More

Highlights

  • Market Capitalization 1.34 billion
  • EBITDA -84169000
  • PE Ratio -0.12
  • Analyst Target Price $32
  • Book Value Per Share $4.76
View More

Share Statistics

  • Shares Outstanding 75.21 million
  • Shares Float 51.09 million
  • % Held by Insiders 1213%
  • % Held by Institutions 93.43%
  • Shares Short 5.29 million
  • Shares Short Prior Month 5.09 million
  • Short Ratio 4.46
  • Short % of Float 15%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 0.86
  • 52 Week High $34.64
  • 52 Week Low $8.12
  • 50 Day Moving Average 24.9
  • 200 Day Moving Average 19.46
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Translate Bio, Inc (TBIO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Translate Bio, Inc (TBIO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A-$0.22-$0.3333.59%
2020-09-302020-11-05$66.45 million$0.23-$0.39159.74%
2020-06-302020-08-06$N/A-$0.58-$0.42-39.76%
2020-03-312020-05-07$N/A-$0.24-$0.4647.61%
2019-12-312020-03-12$3.89 million-$0.48-$0.42-13.42%
2019-09-302019-11-06$1.27 million-$0.35-$0.4622.96%
2019-06-302019-07-31$1.17 million-$0.57-$0.46-24.21%
2019-03-312019-05-09$1.47 million-$0.74-$0.48-54.97%
2018-12-312019-03-21$1.18 million-$0.13-$0.6379.49%
2018-09-302018-11-08$238000-$0.97$0.57-271.44%
2018-06-302018-08-09$N/A-$0.60-$0.623.23%

Translate Bio, Inc (TBIO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Translate Bio, Inc (TBIO) Chart:

Translate Bio, Inc (TBIO) News:

Below you will find a list of latest news for Translate Bio, Inc (TBIO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Translate Bio, Inc (TBIO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Translate Bio, Inc (TBIO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000139506420000122/0001395064-20-000122-index.htm
2019-05-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1693415/000000000019009085/0000000000-19-009085-index.htm
2019-07-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1693415/000000000019010882/0000000000-19-010882-index.htm
2020-03-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1693415/000000000020002440/0000000000-20-002440-index.htm
2018-07-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000031506618002086/0000315066-18-002086-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000031506619001369/0000315066-19-001369-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000031506620001243/0000315066-20-001243-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000083423720008061/0000834237-20-008061-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000089924318019319/0000899243-18-019319-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000089924318019323/0000899243-18-019323-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000089924318019324/0000899243-18-019324-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000089924318019325/0000899243-18-019325-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000089924318019367/0000899243-18-019367-index.htm
2018-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000089924318019455/0000899243-18-019455-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000090342318000373/0000903423-18-000373-index.htm
2018-07-05SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000090342318000378/0000903423-18-000378-index.htm
2018-10-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000090342318000559/0000903423-18-000559-index.htm
2019-05-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000090342319000209/0000903423-19-000209-index.htm
2018-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000095010318008190/0000950103-18-008190-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000095010319001991/0000950103-19-001991-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000110465919006502/0001104659-19-006502-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000110465920010546/0001104659-20-010546-index.htm
2020-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000110465920099718/0001104659-20-099718-index.htm
2018-07-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000114036118031925/0001140361-18-031925-index.htm
2018-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312518214210/0001193125-18-214210-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000119312518244313/0001193125-18-244313-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519001086/0001193125-19-001086-index.htm
2019-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000119312519037831/0001193125-19-037831-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519099925/0001193125-19-099925-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519103315/0001193125-19-103315-index.htm
2019-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1693415/000119312519118007/0001193125-19-118007-index.htm
2019-04-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1693415/000119312519118014/0001193125-19-118014-index.htm
2019-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519133324/0001193125-19-133324-index.htm
2019-05-24S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1693415/000119312519157006/0001193125-19-157006-index.htm
2019-05-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1693415/000119312519157028/0001193125-19-157028-index.htm
2019-05-29CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1693415/000119312519159610/0001193125-19-159610-index.htm
2019-05-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519162962/0001193125-19-162962-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519176469/0001193125-19-176469-index.htm
2019-06-198-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519176475/0001193125-19-176475-index.htm
2019-06-198-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519176477/0001193125-19-176477-index.htm
2019-07-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1693415/000119312519189232/0001193125-19-189232-index.htm
2019-07-03POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1693415/000119312519189234/0001193125-19-189234-index.htm
2019-07-10424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519191885/0001193125-19-191885-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519193612/0001193125-19-193612-index.htm
2019-07-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1693415/000119312519195708/0001193125-19-195708-index.htm
2019-07-22424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519199008/0001193125-19-199008-index.htm
2019-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519207741/0001193125-19-207741-index.htm
2019-07-3110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519207743/0001193125-19-207743-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519243920/0001193125-19-243920-index.htm
2019-09-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519246973/0001193125-19-246973-index.htm
2019-09-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519248177/0001193125-19-248177-index.htm
2019-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519248197/0001193125-19-248197-index.htm
2019-10-258-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519274803/0001193125-19-274803-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000119312519285886/0001193125-19-285886-index.htm
2019-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312519312764/0001193125-19-312764-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520005866/0001193125-20-005866-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000119312520037182/0001193125-20-037182-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1693415/000119312520071633/0001193125-20-071633-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1693415/000119312520072890/0001193125-20-072890-index.htm
2020-03-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1693415/000119312520072895/0001193125-20-072895-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520087031/0001193125-20-087031-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520087488/0001193125-20-087488-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520100578/0001193125-20-100578-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1693415/000119312520115119/0001193125-20-115119-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1693415/000119312520115123/0001193125-20-115123-index.htm
2020-04-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1693415/000119312520128801/0001193125-20-128801-index.htm
2020-05-04S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1693415/000119312520131747/0001193125-20-131747-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000119312520136205/0001193125-20-136205-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520170483/0001193125-20-170483-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520175955/0001193125-20-175955-index.htm
2020-06-24S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1693415/000119312520177633/0001193125-20-177633-index.htm
2020-06-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1693415/000119312520177740/0001193125-20-177740-index.htm
2020-06-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1693415/000119312520180916/0001193125-20-180916-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520180934/0001193125-20-180934-index.htm
2020-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520195485/0001193125-20-195485-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000119312520211886/0001193125-20-211886-index.htm
2020-08-17S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1693415/000119312520222464/0001193125-20-222464-index.htm
2020-08-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1693415/000119312520229383/0001193125-20-229383-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000119312520286833/0001193125-20-286833-index.htm
2019-01-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119001143/0001209191-19-001143-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119001165/0001209191-19-001165-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018945/0001209191-19-018945-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018950/0001209191-19-018950-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018953/0001209191-19-018953-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018956/0001209191-19-018956-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018958/0001209191-19-018958-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018962/0001209191-19-018962-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119018965/0001209191-19-018965-index.htm
2019-04-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119024327/0001209191-19-024327-index.htm
2019-04-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119024329/0001209191-19-024329-index.htm
2019-04-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119026309/0001209191-19-026309-index.htm
2019-04-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119026311/0001209191-19-026311-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119037999/0001209191-19-037999-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119038006/0001209191-19-038006-index.htm
2019-06-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119038011/0001209191-19-038011-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119038015/0001209191-19-038015-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119038018/0001209191-19-038018-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119038020/0001209191-19-038020-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119038022/0001209191-19-038022-index.htm
2019-07-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119042061/0001209191-19-042061-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919119042065/0001209191-19-042065-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120016797/0001209191-20-016797-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120016799/0001209191-20-016799-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120016801/0001209191-20-016801-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120016803/0001209191-20-016803-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120016805/0001209191-20-016805-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037120/0001209191-20-037120-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037123/0001209191-20-037123-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037127/0001209191-20-037127-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037131/0001209191-20-037131-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037372/0001209191-20-037372-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037374/0001209191-20-037374-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000120919120037375/0001209191-20-037375-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000138713120001837/0001387131-20-001837-index.htm
2020-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000139506420000081/0001395064-20-000081-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000139506420000082/0001395064-20-000082-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000139506420000084/0001395064-20-000084-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000139506420000122/0001395064-20-000122-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000149315220002361/0001493152-20-002361-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000156459018028542/0001564590-18-028542-index.htm
2019-03-2110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1693415/000156459019008803/0001564590-19-008803-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1693415/000156459019017973/0001564590-19-017973-index.htm
2019-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1693415/000156761919018056/0001567619-19-018056-index.htm
2019-09-20SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000156761919018588/0001567619-19-018588-index.htm
2019-09-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000156761919018589/0001567619-19-018589-index.htm
2020-05-11SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000156761920009473/0001567619-20-009473-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000156761920012703/0001567619-20-012703-index.htm
2020-08-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1693415/000156761920014641/0001567619-20-014641-index.htm
2019-05-10DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1693415/000169341519000001/0001693415-19-000001-index.htm
2019-05-31EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1693415/999999999519001247/9999999995-19-001247-index.htm
2019-07-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1693415/999999999519001547/9999999995-19-001547-index.htm
2019-07-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1693415/999999999519001654/9999999995-19-001654-index.htm
2020-05-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1693415/999999999520001023/9999999995-20-001023-index.htm
2020-02-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1693415/999999999720000690/9999999997-20-000690-index.htm
2020-02-26SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1693415/999999999720001022/9999999997-20-001022-index.htm

Translate Bio, Inc (TBIO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Translate Bio, Inc (TBIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1213%
Institutional Ownership: 9343%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-30Shire Human Genetic Therapies, Inc.10% Share HolderSell6,824,992.0020.68141,140,834.560.00https://www.sec.gov/Archives/edgar/data/1693415/000139506420000122/0001395064-20-000122-index.htm
2020-06-26BAUPOST GROUP LLC/MA10% Share HolderBuy500,000.0022.0011,000,000.0018,044,239.00https://www.sec.gov/Archives/edgar/data/1693415/000156761920012703/0001567619-20-012703-index.htm
2018-07-02MRL Ventures Fund LLC10% Share HolderBuy25,000.0013.00325,000.001,873,503.00https://www.sec.gov/Archives/edgar/data/1693415/000089924318019325/0000899243-18-019325-index.htm
2018-07-02Brian M. Jr. GallagherDirectorBuy269,230.0013.003,499,990.003,697,912.00https://www.sec.gov/Archives/edgar/data/1693415/000089924318019455/0000899243-18-019455-index.htm
2018-07-02PLC GLAXOSMITHKLINE10% Share HolderBuy269,230.0013.003,499,990.003,697,912.00https://www.sec.gov/Archives/edgar/data/1693415/000090342318000373/0000903423-18-000373-index.htm
2020-08-27JEAN FRANCOIS FORMELADirectorSell10,097.0014.38145,217.073,833,122.00https://www.sec.gov/Archives/edgar/data/1693415/000110465920099718/0001104659-20-099718-index.htm
2020-08-26JEAN FRANCOIS FORMELADirectorSell44,381.0014.80656,745.603,843,219.00https://www.sec.gov/Archives/edgar/data/1693415/000110465920099718/0001104659-20-099718-index.htm
2020-08-25JEAN FRANCOIS FORMELADirectorSell34,410.0015.00516,160.323,887,600.00https://www.sec.gov/Archives/edgar/data/1693415/000110465920099718/0001104659-20-099718-index.htm
2020-06-03Shire Human Genetic Therapies, Inc.10% Share HolderSell40,086.0019.75791,698.506,824,992.00https://www.sec.gov/Archives/edgar/data/1693415/000139506420000084/0001395064-20-000084-index.htm
2020-06-02Shire Human Genetic Therapies, Inc.10% Share HolderSell5,006.0020.02100,220.126,865,078.00https://www.sec.gov/Archives/edgar/data/1693415/000139506420000082/0001395064-20-000082-index.htm
2020-06-02Shire Human Genetic Therapies, Inc.10% Share HolderSell100,389.0019.751,982,682.756,870,084.00https://www.sec.gov/Archives/edgar/data/1693415/000139506420000082/0001395064-20-000082-index.htm
2020-06-01Shire Human Genetic Therapies, Inc.10% Share HolderSell1,400.0020.5328,742.006,970,473.00https://www.sec.gov/Archives/edgar/data/1693415/000139506420000082/0001395064-20-000082-index.htm
2020-06-01Shire Human Genetic Therapies, Inc.10% Share HolderSell107,072.0019.852,125,379.206,971,873.00https://www.sec.gov/Archives/edgar/data/1693415/000139506420000082/0001395064-20-000082-index.htm